ishares Inflation Hedged Us Aggregate Bond ETF (AGIH) News

Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib

Company to present pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies at the European Society of Medical Oncology (ESMO) Congress...

Form PRER14A - Preliminary Proxy Soliciting materials

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1...

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by...

Form PRER14A - Preliminary Proxy Soliciting materials

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial...

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by...

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025...

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches...

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025...

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

NUV-1511 is the Company’s first drug-drug conjugate (DDC) to enter the clinic Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company...